ClinicalTrials.gg

Program

ACC017

A development code. Also written as “ACC017+FTC/TAF” and “ACC017 tablets”.

Its studies are mostly in Infections, led by Jiangsu Aidea Pharmaceutical Group.

Furthest: phase 2, since Nov 26, 20244 company-led studies, 2 open or runningNext primary completion: Jun 30, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Jiangsu Aidea Pharmaceutical Group42 open or runningphase 2since Nov 26, 2024Jan 23, 2024Jun 30, 2027phase 2 · NCT07711210

Also a collaborator on its studies: chengdu-aidea-pharmaceutical-technology-co-ltd.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jan 23, 2024First study: phase 1 study in Healthy Adult ParticipantsFirst studyNCT06278389 · 48 enrolled · China
  2. Nov 26, 2024Phase 2 study in InfectionsNCT06719310 · 36 enrolled · China
  3. Jul 7, 20262 phase 2 studies in InfectionsNCT07711223, NCT07711210

Ahead

  1. Jun 30, 2027Primary completion: phase 2 study in InfectionsNCT07711210
  2. Aug 31, 2028Primary completion: phase 2 study in InfectionsNCT07711223

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 4 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07711223Infections · China2RecruitingAug 31, 2028660
NCT07711210Infections · China2Active, not recruitingJun 30, 202712
NCT06719310Infections · China2CompletedApr 28, 202536
NCT06278389Healthy Adult Participants · China1CompletedMay 20, 202448

How it is read

Names in the registry

  • “ACC017+FTC/TAF”, 2 entries
  • “ACC017 tablets”, 1 entry
  • “ACC017”, 1 entry

Codes read as this program: ACC017.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.